Business Context and Reporting Period
Company: MYOMO, INC.
Filing Type: Form 8-K (Current Report)
Date of Report: February 8, 2019
Event: Entry into a Material Definitive Agreement for a public offering of common stock.
Key Financial Metrics and Transaction Details
- Shares Offered: 3,950,000 shares of Common Stock.
- Offering Price: $1.40 per share.
- Expected Gross Proceeds: Approximately $5.5 million (before underwriting discount and expenses).
- Underwriter Option: 45-day option to purchase up to 592,500 additional shares at the offering price.
- Underwriter Warrant: Issued to purchase shares equal to 8.0% of the shares sold in the offering.
- Warrant Exercise Price: 125% of the public offering price ($1.75 per share).
- Warrant Terms: Exercisable six months from issuance; expires four years from issuance.
- Closing Date: Expected on or about February 12, 2019.
Material Changes and Adjustments
2017 Warrant Adjustment: The sale of Common Stock at $1.40 per share triggered a downward adjustment to the exercise price of outstanding warrants issued in December 2017 ("2017 Warrants").
- Previous Exercise Price: $2.95 per share.
- New Exercise Price: $1.40 per share.
Outlook, Risks, and Management Commentary
Management Commentary: The Company entered into an underwriting agreement with National Securities Corporation to raise capital. The offering is conducted pursuant to a shelf registration statement (Form S-3) declared effective on July 16, 2018.
Risks and Contingencies: The closing of the offering is subject to the satisfaction of customary closing conditions. The Underwriting Agreement contains customary representations, warranties, covenants, and termination provisions. The filing explicitly states that the representations and warranties were made solely for the benefit of the parties to the agreement and may be subject to limitations.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds received after deducting underwriting discounts and expenses.
- Confirm whether the Underwriter exercises the option to purchase the additional 592,500 shares.
- Review the final prospectus supplement for updated risk factors and use of proceeds.
- Monitor the dilution impact from the issuance of the Underwriter Warrant (8.0% of shares sold) and the adjusted 2017 Warrants.
- Check subsequent filings for the actual exercise of the 2017 Warrants at the new $1.40 price.